Pictet Asset Management
SYRE icon

Pictet Asset Management’s Spyre Therapeutics SYRE Stock Holding History

Pictet Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.8M Buy
628,138
+136,489
+28% +$9.96M 0.05% 314
2026
Q1 		$24.8M Sell
491,649
-422,311
-46% -$15.9M 0.03% 452
2025
Q4 		$29.9M Sell
913,960
-122,258
-12% -$3.19M 0.03% 427
2025
Q3 		$17.4M Sell
1,036,218
-43,225
-4% -$705K 0.02% 551
2025
Q2 		$16.2M Buy
1,079,443
+10,551
+1% +$156K 0.02% 560
2025
Q1 		$17.2M Sell
1,068,892
-23,232
-2% -$483K 0.02% 532
2024
Q4 		$25.4M Buy
1,092,124
+266,418
+32% +$7.81M 0.03% 436
2024
Q3 		$24.3M Buy
825,706
+439,089
+114% +$12.2M 0.03% 438
2024
Q2 		$9.09M Buy
+386,617
New +$13M 0.01% 647

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Pictet Asset Management's SYRE Position: Q2 2026 in Review

Pictet Asset Management increased its Spyre Therapeutics (SYRE) stake by 28% in Q2 2026, buying an estimated $9.96M and bringing the position to 628,138 shares worth $55.8M. The position accounts for 0.05% of the portfolio, ranked #314.

Pictet Asset Management first reported a position in SYRE in Q2 2024 and has held it in 9 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Pictet Asset Management held 628,138 shares of Spyre Therapeutics worth $55.8M as of Q2 2026.
  • Pictet Asset Management bought 136,489 Spyre Therapeutics shares in Q2 2026, an estimated $9.96M.
  • Spyre Therapeutics made up 0.05% of Pictet Asset Management's portfolio in Q2 2026, its #314 holding.
  • Pictet Asset Management first reported a position in Spyre Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.